Fig. 2From: A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe diseaseReveglucosidase alfa exposure-dose linearity over 24Â weeks of treatment. Exposure data presented as AUC0-inf on day 1, week 12, and week 24 of dosing. Abbreviation: AUC0-inf, area under the concentration-time curve from 0Â h extrapolated to infinityBack to article page